Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia

Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation

(2014) Ion Cristóbal et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56  stabilizes its antiapoptotic activity

(2014) I. C. C. Low et al.   BLOOD

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

(2014) A. Agarwal et al.   CLINICAL CANCER RESEARCH

Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia

(2014) Alejandro Gutierrez et al.   JOURNAL OF CLINICAL INVESTIGATION

PP2A: The Achilles Heal in MDS with 5q Deletion

(2014) David A. Sallman et al.   Frontiers in Oncology

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Structural basis of protein phosphatase 2A stable latency

(2013) Li Jiang et al.   Nature Communications

Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles

(2012) Laura Mosca et al.   AMERICAN JOURNAL OF HEMATOLOGY

STAR: ultrafast universal RNA-seq aligner

(2012) Alexander Dobin et al.   BIOINFORMATICS

Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis

(2012) Sahar A. Saddoughi et al.   EMBO Molecular Medicine

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response

(2012) Jaya Sangodkar et al.   JOURNAL OF CLINICAL INVESTIGATION

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

(2012) Christina Curtis et al.   NATURE

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

(2012) Rocco Piazza et al.   NATURE GENETICS

Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2PP2A/SET

(2011) Lisette Arnaud et al.   FEBS LETTERS

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

(2011) I. Cristobal et al.   HAEMATOLOGICA

Reactivating PP2A by FTY720 as a Novel therapy for AML with C-KIT tyrosine kinase domain mutation

(2011) Yan Yang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

(2011) I Cristóbal et al.   LEUKEMIA

Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy

(2011) C H Switzer et al.   ONCOGENE

CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis

(2010) Qian-Ze Dong et al.   ANNALS OF SURGICAL ONCOLOGY

Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-KIT Suggests PP2A Reactivation as a Strategy to Treat c-KIT+ Cancers

(2010) K. G. Roberts et al.   CANCER RESEARCH

Differential expression analysis for sequence count data

(2010) Simon Anders et al.   GENOME BIOLOGY

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

(2009) I. Cristobal et al.   BLOOD

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SV40 small T antigen and PP2A phosphatase in cell transformation

(2008) Anna A. Sablina et al.   CANCER AND METASTASIS REVIEWS